🚀 VC round data is live in beta, check it out!
Barinthus Biotherapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Barinthus Biotherapeutics and similar public comparables like Boundless Bio, IO Biotech, Cue Biopharma, Vistagen Therapeutics and more.
Barinthus Biotherapeutics Overview
About Barinthus Biotherapeutics
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
Founded
2016
HQ
Employees
105
Website
Sectors
Financials (LTM)
Market Cap
$25M
Barinthus Biotherapeutics Financials
Barinthus Biotherapeutics reported last 12-month revenue of —.
In the same LTM period, Barinthus Biotherapeutics generated had net loss of ($64M).
Revenue (LTM)
Barinthus Biotherapeutics P&L
In the most recent fiscal year, Barinthus Biotherapeutics reported revenue of $15M and EBITDA of ($55M).
Barinthus Biotherapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $15M | XXX | XXX | XXX |
| EBITDA | — | XXX | ($55M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (370%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (346%) | XXX | XXX | XXX |
| Net Profit | ($64M) | XXX | ($61M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (408%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Barinthus Biotherapeutics Stock Performance
Barinthus Biotherapeutics has current market cap of $25M.
Market Cap Evolution
Barinthus Biotherapeutics' stock price is $0.61.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $25M | 0.0% | XXX | XXX | XXX | $-1.50 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBarinthus Biotherapeutics Valuation Multiples
Barinthus Biotherapeutics trades at (2.5x) EV/Revenue multiple, and 0.7x EV/EBITDA.
EV / Revenue (LTM)
Barinthus Biotherapeutics Financial Valuation Multiples
As of March 18, 2026, Barinthus Biotherapeutics has market cap of $25M.
Equity research analysts estimate Barinthus Biotherapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Barinthus Biotherapeutics has a P/E ratio of (0.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $25M | XXX | $25M | XXX | XXX | XXX |
| EV (current) | ($38M) | XXX | ($38M) | XXX | XXX | XXX |
| EV/Revenue | — | XXX | (2.5x) | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBIT | 0.6x | XXX | 0.7x | XXX | XXX | XXX |
| P/E | (0.4x) | XXX | (0.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 1.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Barinthus Biotherapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Barinthus Biotherapeutics Margins & Growth Rates
Barinthus Biotherapeutics' revenue in the last fiscal year declined by (100%).
Barinthus Biotherapeutics' revenue per employee in the last FY averaged $0.0M.
Barinthus Biotherapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (370%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (22%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 198% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 256% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 446% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Barinthus Biotherapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Boundless Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| IO Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Cue Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Vistagen Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Skye Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Barinthus Biotherapeutics M&A Activity
Barinthus Biotherapeutics acquired XXX companies to date.
Last acquisition by Barinthus Biotherapeutics was on XXXXXXXX, XXXXX. Barinthus Biotherapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Barinthus Biotherapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBarinthus Biotherapeutics Investment Activity
Barinthus Biotherapeutics invested in XXX companies to date.
Barinthus Biotherapeutics made its latest investment on XXXXXXXX, XXXXX. Barinthus Biotherapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Barinthus Biotherapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Barinthus Biotherapeutics
| When was Barinthus Biotherapeutics founded? | Barinthus Biotherapeutics was founded in 2016. |
| Where is Barinthus Biotherapeutics headquartered? | Barinthus Biotherapeutics is headquartered in United Kingdom. |
| How many employees does Barinthus Biotherapeutics have? | As of today, Barinthus Biotherapeutics has over 105 employees. |
| Who is the CEO of Barinthus Biotherapeutics? | Barinthus Biotherapeutics' CEO is William J. Enright. |
| Is Barinthus Biotherapeutics publicly listed? | Yes, Barinthus Biotherapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Barinthus Biotherapeutics? | Barinthus Biotherapeutics trades under BRNS ticker. |
| When did Barinthus Biotherapeutics go public? | Barinthus Biotherapeutics went public in 2021. |
| Who are competitors of Barinthus Biotherapeutics? | Barinthus Biotherapeutics main competitors are Boundless Bio, IO Biotech, Cue Biopharma, Vistagen Therapeutics. |
| What is the current market cap of Barinthus Biotherapeutics? | Barinthus Biotherapeutics' current market cap is $25M. |
| What is the current revenue growth of Barinthus Biotherapeutics? | Barinthus Biotherapeutics revenue growth (vs. last FY) is (100%). |
| What is the current EV/Revenue multiple of Barinthus Biotherapeutics? | Current revenue multiple of Barinthus Biotherapeutics is (2.5x). |
| Is Barinthus Biotherapeutics profitable? | No, Barinthus Biotherapeutics is not profitable. |
| What is the current net income of Barinthus Biotherapeutics? | Barinthus Biotherapeutics' last 12 months net income is ($64M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.